UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
NCT Number: NCT06090643
This clinical trial implements research strategies to increase colorectal cancer (CRC) screening rates among low income and ethnic minority groups. CRC is the second most common cause of cancer mortality in the United States and disproportionately burdens low income and ethnic minority groups. Fecal immunochemical testing (FIT) is a test to check for blood in the stool. A brush is used to collect water drops from around the surface of a stool while it is still in the toilet bowl. The samples are then sent to a laboratory, where they are checked for a human blood protein. Blood in the stool may be a sign of colorectal cancer. Despite its potential for reducing CRC incidence and mortality, screening remains woefully underutilized. There is an unmet need for practical and effective programs to improve CRC screening rates. By implementing a culturally-tailored screening CRC program that supports providers and clinic staff to encourage eligible patients to complete FIT, researchers hope to reduce cancer disparities among low-income and ethnic groups and increase the CRC screening rate, which will help providers find CRC sooner, when it may be easier to treat.
This study is active but is not currently recruiting participants.
Notify Me50 year–75 year
All sexes
Interventional
Not applicable
Los Angeles, California, 90095, United States
PRIMARY OBJECTIVE:
I. To increase CRC screening rates within Northeast Valley Health Corporation (NEVHC).
OUTLINE: Clinic sites are randomized to 1 of 2 groups.
GROUP I CLINICS: Physicians and clinic staff receive ongoing training, education, and feedback on CRC screening, and utilize point-of-care clinical decision support tool throughout the trial. Patients receive CRC screening recommendations from provider, a FIT kit with culturally tailored instructions, consultation with clinic staff, and text message reminders throughout the trial.
GROUP II CLINICS: Physicians and clinic staff provide and patients receive CRC screening usual care throughout the trial.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Receive CRC screening usual care
Other names: standard of care, standard therapy
Receive consultation with clinic staff
Other names: Consult
Receive education and training on CRC screening
Other names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Ancillary studies
Receive FIT kit with culturally tailored instructions
Other names: FIT, iFOBT, immunoassay fecal occult blood test, immunochemical fecal occult blood test, Immunochemical FOBT, immunologic fecal occult blood test
Receive feedback on CRC screening
Receive CRC screening recommendations
Utilize clinical decision support tool
Receive text message reminders
Other names: Automated Text Message-Based Navigation, Text Message-Based Navigation
Time frame: Up to 3 years
Patient-level study data on the primary outcome of CRC screening receipt will be assessed through electronic health record data systems. Fecal immunochemical test (FIT) is the screening method most commonly utilized in NEVHC. Patients who have completed a FIT within the past 12 months will be considered screened. Consistent with current CRC screening guidelines, patients screened via a flexible sigmoidoscopy in the past five years (very rare) or colonoscopy (very small numbers) in the past ten years will also be considered screened. The data will be analyzed using generalized linear mixed models that account for clustering within clinic and provider and multiple observations within patients.
Time frame: Up to 3 years
Missed opportunity rates will be calculated at baseline, end of study, and intermediate time points by determining the number of eligible patients who made a clinic visit but did not receive a FIT kit. The data will be analyzed using generalized linear mixed models that account for clustering within clinic and provider and multiple observations within patients.
Time frame: Up to 3 years
The data will be analyzed using generalized linear mixed models that account for clustering within clinic and provider and multiple observations within patients.
Jonsson Comprehensive Cancer Center
Other
Implementation Research to Reduce Colorectal Cancer Disparities
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02465060
Adenocarcinoma, Adnexal Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT03822572
Colonic Diseases, Colorectal Carcinoma
Salzburg, State of Salzburg, Austria
View Trial DetailsNCT07229443
Colonic Diseases, Colorectal Carcinoma
Los Angeles, California, United States
View Trial DetailsNCT07118176
Adenocarcinoma, Adnexal Diseases
Los Angeles, California, United States
View Trial Details